Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Vemurafenib × Clear all

Phase

Phase 1 20 Phase 2 14 Phase 3 9 Phase 4 3 Phase 1/2 2 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 29 Carboplatin 28 Gemcitabine 27 pembrolizumab 25 Paclitaxel 25 Capecitabine 16 Pemetrexed 15 Bevacizumab 15 Docetaxel 14 Oxaliplatin 13 Drug Therapy 12 Fluorouracil 11 Nivolumab 10 130-nm albumin-bound paclitaxel 9 anlotinib 7 Trastuzumab 7 Rituximab 6 Injections 6 atezolizumab 5 Temozolomide 5 Leucovorin 5 Ipilimumab 5 Lenalidomide 4 Irinotecan 4 Interferon alpha-2 4 Folfox protocol 4 Albumin-Bound Paclitaxel 4 venetoclax 3 sintilimab 3 pertuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03178552 2026-03-09

B-FAST

Hoffmann-La Roche

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡